California’s Applied Molecular Transport has become the latest biotech to go for an IPO during the pandemic, aiming to raise $100 million to take an oral ulcerative colitis drug into phase 2 ...
You're currently following this author! Want to unfollow? Unsubscribe via the link in your email. Follow Pete Syme Every time Pete publishes a story, you’ll get an alert straight to your inbox! Enter ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback